Literature DB >> 4056340

Blood analysis for liver cirrhosis.

E G Hahn.   

Abstract

Liver fibrosis is one of the most important factors of disturbed liver function, but could not be measured by simple blood tests until recently. Among several parameters used for this purpose, the aminoterminal procollagen type III peptide (PIIIP) appears to be the most widely accepted. Studies conducted in several clinical groups have shown that PIIIP effectively distinguishes between non-fibrotic and fibrotic liver disease. A reliable commercial kit is available and a wide application possible to evaluate the clinical meaning of serum PIIIP for the long-term outcome of chronic liver disease. With this novel blood test we can now assess liver fibrosis as we can measure the hepato-biliary function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4056340     DOI: 10.1016/s0168-8278(85)80069-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Type I and type III procollagen peptides during hepatic fibrogenesis. An immunohistochemical and ELISA serum study in the CCl4 rat model.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

2.  Elevated procollagen-III-peptide in myositis ossificans progressiva.

Authors:  W Kullich; G Klein
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

3.  Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; F K Mathiesen; T M Hansen; I Lorenzen
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

4.  An immunohistochemical and serum ELISA study of type I and III procollagen aminopropeptides in primary biliary cirrhosis.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

5.  Assessment of the fibrogenetic activity in chronic pancreatitis. The role of circulating levels of extracellular matrix components.

Authors:  J E Domínguez-Muñoz; G Manes; M Büchler; P Malfertheiner
Journal:  Int J Pancreatol       Date:  1993-12

6.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

Review 7.  A review of new approaches to assessing hepatic function in animals.

Authors:  C E Cornelius
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

8.  Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.

Authors:  F Serejo; A Costa; A G Oliveira; F Ramalho; A Batista; M C De Moura
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

9.  Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.

Authors:  M Bührer; J Y Le Cotonnec; M Wermeille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Serum laminin--its concentration increases with portal hypertension in cirrhotic liver disease.

Authors:  A M Gressner; W Tittor
Journal:  Klin Wochenschr       Date:  1986-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.